期刊文献+

利用TCRVβ家族CDR3长度分析检测HCL和c-ALL的克隆性增殖T细胞 被引量:2

ANALYSIS OF T CELL CLONALITY BY CDR3 SIZE OF T CELL ANTIGEN RECEPTOR Vβ REPERTOIRE IN HCL AND C ALL
下载PDF
导出
摘要 目的推介检测分析T细胞克隆性增殖的新方法,探讨判别恶性肿瘤免疫状态的新途经。方法应用RT-PCR检测T细胞受体(TCR)Vβ24个亚家族的互补决定区3(CDR3)长度,并经基因扫描(genescan)分析检测3例多毛细胞白血病(HCL)和1例普通型急性淋巴细胞白血病(c-ALL)病人外周血的T细胞克隆性。结果4例病人的部分Vβ家族的扩增产物出现单峰(单克隆)或—主峰(寡克隆)图像,而正常对照的全部PCR产物呈多峰(多克隆)图像。结论HCL和c-ALL病人外周血中存在克隆性生殖T细胞,可能是宿主对白血病抗原的一种直接反应。 Objective To Analyse of T Cell clonality by CDR3 sige of T cell antigen receptor Vβ repertoire in HCL and C ALL.Methods Peripheral blood mononuclear cell samples from 3 cases of HCL and 1 case of c ALL were investigated for CDR3(conplementarity determining region 3) size analysis of T cell receptor Vβ repertoir using reverse transcriptase polymerase chain reaction(RT CPR). The products were further analyzed by genescan to identify T cell clonality. Results The results showed that some Vβ subfamily PCR products from 4 patients comtained monopeak(monoclone) or a dominant peak(oligoclone). In contrast multipeak(polyclone) distributions were found in all Vβ subfamily PCR products from normal control cases. Conclusion T cell clonal expansion may be found in HCL and c ALL cases that may indicate a host respones directed against leukemia related antigen. In addition, it may be useful to detect the minimal residual disease.
机构地区 暨南大学医学院
出处 《白血病》 CAS 1999年第1期19-21,共3页
关键词 T细胞受体β CDR3 基因扫描 急性白血病 T cell receptor β Leukemia T cell clonality Genescan
  • 相关文献

参考文献1

共引文献23

同被引文献22

  • 1李扬秋,刘启发.血液肿瘤靶向治疗和免疫治疗[J].肿瘤防治研究,2004,31(6). 被引量:5
  • 2Ohminami H, Yasukawa M, Kaneko S, et al.Fas- independent and nonapoptotic cytotoxicity mediated by a human CD+4 T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide[J]. Blood, 1999, 93(3):925-935.
  • 3Azuma T, Otsuki T, Kuzushima K, et al.Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1 -specific cytotoxic T lymphocytes [J].Clin Cancer Res, 2004, 10(21):7402-7412.
  • 4Schag K, Schmidt S M, Muller M R, et al. Identification of C - met oncogene as a broadly expressed tumor- associated antigen recognized by cytotoxic T-lymphocytes [J]. Clin Cancer Res, 2004, 10(11):3658-3666.
  • 5Schroers R, Shen L, Rollins L, et al. Human telomerase reverse transcriptase- specific Thelper responses induced by promiscuous major histocompatibility complex class Ⅱ-restricted epitopes[J]. Clin Cancer Res, 2003, 9(13):4743 -4755.
  • 6Reker S, Meier A, Holten-Andersen L, et al.Identification of novel survivin-derived CTL epitopes[J]. Cancer Biol Ther, 2004, 3 (2):173-179.
  • 7Bae J, Martinson J A, Klingemann H G. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against Bcell malignancies[J]. Clin Cancer Res, 2005,11 (4): 1629-1638.
  • 8Bae J, Martinson J A, Klingemann H G. Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity [J].Clin Cancer Res, 2004, 10(20):7043-7052.
  • 9Sadovnikova E, Parovichnikova E N, Savchenko V G, et al. The CD68 protein as a potential target for leukaemia-reactive CTL [J].Leukemia, 2002, 16(10):2019-2026.
  • 10Wen Y J, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma:evidence for their capacity to lyse autologous primary tumor cells[J]. Blood, 2001, 97(6):1750-1755.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部